Get the Stockscreener App
8.56
0.00%
0.00
Pre-market:
8.51
-0.05
-0.58%
Candel Therapeutics Inc stock is traded at $8.56, with a volume of 1.63M.
It is up +0.00% in the last 24 hours and down -2.39% over the past month.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$8.56
Open:
$8.7
24h Volume:
1.63M
Relative Volume:
0.91
Market Cap:
$627.19M
Revenue:
$31,000
Net Income/Loss:
$-54.42M
P/E Ratio:
-8.7543
EPS:
-0.9778
Net Cash Flow:
$-48.99M
1W Performance:
+0.71%
1M Performance:
-2.39%
6M Performance:
+48.35%
1Y Performance:
+66.86%
1-Day Range:
$8.305
$8.92
1-Week Range:
$8.10
$8.985
52-Week Range:
$4.35
$9.5699
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
8.56 | 627.19M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Candel Therapeutics eyes year-end BLA after strong prostate cancer data - MSN
trust me - Moomoo
Avoiding Lag: Real-Time Signals in (CADL) Movement - Stock Traders Daily
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish - TradingView
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Candel Therapeutics, Inc. posts new long term trial results for aglatimagene besadenovec - Traders Union
Candel Therapeutics stock falls despite phase 3 trial publication - Investing.com
CADL Achieves Significant Milestone in Prostate Cancer Treatment - GuruFocus
Candel publishes phase 3 prostate cancer trial results - Investing.com UK
Candel Therapeutics stock falls despite phase 3 trial publication By Investing.com - Investing.com South Africa
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - The Manila Times
Candel publishes phase 3 prostate cancer trial results By Investing.com - Investing.com Australia
Candel Therapeutics Announces Publication in The Lancet - GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bank of America Securities Remains a Hold on Candel Therapeutics (CADL) - The Globe and Mail
New hires at Candel Therapeutics get 63,000 stock options - Stock Titan
BofA Securities Maintains Candel Therapeutics(CADL.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Discipline and Rules-Based Execution in CADL Response - Stock Traders Daily
Candel Therapeutics reported better-than-feared Q1 loss – but all eyes turn to this pivotal event tomorrow - MSN
Candel Therapeutics (CADL) Edges Higher, Holds Above Key Support LevelHigh Dividend Factor - thelegaladvocate.com
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - simplywall.st
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade - MSN
Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data - TradingView
Candel Therapeutics, Inc. reveals strategy for advancing prostate cancer and glioma programs - Traders Union
Behavioral Patterns of CADL and Institutional Flows - Stock Traders Daily
Candel Therapeutics reports positive phase 3 prostate cancer trial data - MSN
BofA Securities Maintains Candel Therapeutics(CADL.US) With Hold Rating, Raises Target Price to $9 - Moomoo
BofA raises Candel Therapeutics stock price target on prostate cancer data - Investing.com UK
BofA raises Candel Therapeutics stock price target on prostate cancer data By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data - Dailyhunt
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data - The Globe and Mail
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):